Provider education · Lipids
Apolipoprotein B (ApoB): clinical use in practice.
By New Century Labs · Last updated July 6, 2026
Apolipoprotein B counts the atherogenic particles that a standard cholesterol number only estimates. This guide is for the ordering clinician: what ApoB reflects, when it clarifies a lipid picture, and how to fold it into risk assessment.
What the test measures
Every atherogenic lipoprotein particle carries exactly one apolipoprotein B molecule. Measuring ApoB therefore gives a direct count of these particles, including LDL, VLDL, IDL, and lipoprotein(a). It answers a question that LDL cholesterol only approximates: how many particles are circulating, not just how much cholesterol they carry.
That distinction matters because particle number and cholesterol content can diverge. Two patients with the same LDL-C can carry very different particle burdens, and ApoB resolves that ambiguity with a single measurement.
When clinicians may consider ordering
ApoB is often ordered when the standard lipid panel leaves risk uncertain or potentially understated. Clinicians commonly reach for it in situations such as:
- discordance between LDL-C and clinical risk, particularly with high triglycerides or metabolic syndrome;
- diabetes or insulin resistance, where particle number can outpace measured cholesterol;
- tracking response to a lipid-lowering strategy on a consistent, particle-based metric;
- refining risk when LDL-C sits near a decision threshold.
ApoB and lipoprotein(a) answer different questions: ApoB captures total atherogenic particle number, while Lp(a) reflects an inherited, largely fixed component of risk. Many workups use them together. See the Lp(a) guide for that companion measure.
At a glance · Ordering logistics
- Quest order code
- 91726
- Fasting
- Yes, 10–12 hours
- Specimen
- Serum
- Typical turnaround
- Typically several business days
- Reference range
- No single reference interval; risk-based cut points apply (<90 mg/dL optimal)
Performed through our national laboratory network. Draw access is nationwide; results return to the ordering provider.
Interpreting the result
ApoB is read as a measure of atherogenic particle burden: higher values indicate more circulating particles and, generally, greater cardiovascular risk. It is most informative alongside the lipid panel and the clinical picture rather than in isolation, and it is a risk marker, not a diagnosis. Reference thresholds and treatment targets vary with guideline and patient context, so apply the interpretive framework you already use in practice.
Ordering, interpretation, and any resulting management remain the responsibility of the licensed provider, and nothing here is a treatment recommendation.
Practical notes for ordering
ApoB uses a serum specimen and calls for a 10–12 hour fast, so it slots in alongside a fasting lipid panel on the same draw. Turnaround is typically several business days. Patients can complete the draw at CLIA-certified sites nationwide, and results return to the ordering provider.
Because ApoB tracks a lipid-lowering strategy on a stable particle-based metric, it lends itself to serial ordering when you want a consistent yardstick across visits. Interval and interpretation are your call.
Next step
Bring ApoB into your lipid workups.
Set up ordering through our national laboratory network, with nationwide patient draw access.